Avidity Biosciences Inc (NASDAQ: RNA) closed the day trading at $22.69 up 7.94% from the previous closing price of $21.02. In other words, the price has increased by $+1.67 from its previous closing price. On the day, 1219817 shares were traded.
Ratios:
For a better understanding of RNA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.58 and its Current Ratio is at 7.58. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On March 31, 2023, Evercore ISI Downgraded its rating to In-line which previously was Outperform but kept the price unchanged to $20.
On July 20, 2022, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $29.Chardan Capital Markets initiated its Buy rating on July 20, 2022, with a $29 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 12 ’24 when Boyce Sarah sold 28,000 shares for $22.63 per share. The transaction valued at 633,682 led to the insider holds 112,117 shares of the business.
LEVIN ARTHUR A sold 27,641 shares of RNA for $609,017 on Mar 12 ’24. The Director now owns 14,830 shares after completing the transaction at $22.03 per share. On Mar 08 ’24, another insider, Boyce Sarah, who serves as the President and CEO of the company, sold 84,000 shares for $21.39 each. As a result, the insider received 1,796,710 and left with 112,117 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 1.81B and an Enterprise Value of 1.22B. For the stock, the TTM Price-to-Sale (P/S) ratio is 189.21 while its Price-to-Book (P/B) ratio in mrq is 3.59. Its current Enterprise Value per Revenue stands at 127.96 whereas that against EBITDA is -5.24.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $22.46, while it has fallen to a 52-week low of $4.82. The 50-Day Moving Average of the stock is 13.49, while the 200-Day Moving Average is calculated to be 9.58.
Shares Statistics:
Over the past 3-months, RNA traded about 1.20M shares per day on average, while over the past 10 days, RNA traded about 1.95M shares per day. A total of 79.28M shares are outstanding, with a floating share count of 70.74M. Insiders hold about 11.27% of the company’s shares, while institutions hold 98.37% stake in the company. Shares short for RNA as of Feb 29, 2024 were 7.77M with a Short Ratio of 6.50, compared to 7.64M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.74% and a Short% of Float of 9.86%.
Earnings Estimates
Current recommendations for the stock of the company come from 6 analysts. On average, analysts expect EPS of -$0.78 for the current quarter, with a high estimate of -$0.67 and a low estimate of -$0.95, while EPS last year was -$0.74. The consensus estimate for the next quarter is -$0.79, with high estimates of -$0.67 and low estimates of -$0.99.
Analysts are recommending an EPS of between -$2.71 and -$4.19 for the fiscal current year, implying an average EPS of -$3.2. EPS for the following year is -$3.58, with 6 analysts recommending between -$2.61 and -$4.65.
